

**Rat Peroxisome Proliferator-Activated
Receptor Alpha
(nr1c1, pparA, rPPAR α)
Reporter Assay System**

3x 32 Assays in 96-well Format
Product # R00111-32

▪


Technical Manual
(version 7.2)

www.indigobiosciences.com

3006 Research Drive, Suite A1, State College, PA 16801, USA

Customer Service:
814-234-1919; FAX 814-272-0152
customerserv@indigobiosciences.com

Technical Service:
814-234-1919
techserv@indigobiosciences.com



Rat PPAR α Reporter Assay System 96-well Format Assays

I. Description	
▪ The Assay System.....	3
▪ The Assay Chemistry.....	3
▪ Preparation of Test Compounds.....	4
▪ Assay Scheme.....	4
▪ Assay Performance.....	5
II. Product Components & Storage Conditions	7
III. Materials to be Supplied by the User	7
IV. Assay Protocol	
▪ A word about <i>Antagonist</i> -mode assay setup.....	8
▪ <i>DAY 1 Assay Protocol</i>	8
▪ <i>DAY 2 Assay Protocol</i>	10
V. Related Products	11
VI. Limited Use Disclosures	12
APPENDIX 1: Example Scheme for Serial Dilutions	12

I. Description

▪ The Assay System ▪

This nuclear receptor assay utilizes proprietary non-human cells engineered to provide constitutive, high-level expression of the **Peroxisome Proliferator-Activated Receptor Alpha** (nr1c1), a ligand-dependent transcription factor commonly referred to as pparA or **rPPAR α** .

INDIGO's Reporter Cells include the luciferase reporter gene functionally linked to a PPAR α -responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in rPPAR α activity. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against rPPAR α .

Rat PPAR α Reporter Cells are prepared using INDIGO's proprietary **CryoMite™** process. This cryo-preservation method yields exceptional cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spin-and-rinse of cells or viability determinations prior to assay setup.

INDIGO's Nuclear Receptor assays are all-inclusive cell-based assay systems. In addition to Rat PPAR α Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user's test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate.

▪ The Assay Chemistry ▪

INDIGO's nuclear receptor assay kits capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg⁺²-dependent reaction that consumes O₂ and ATP as co-substrates, and yields as products oxyluciferin, AMP, PP_i, CO₂, and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

INDIGO's Nuclear Receptor Assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

▪ Preparation of Test Compounds ▪

Test compounds are typically solvated at high concentration in DMSO and stored frozen as master stocks. Immediately prior to setting up an assay, the master stocks are serially diluted using **Compound Screening Medium (CSM)** (as described in *Step 7*) to achieve the desired assay concentrations. Do not use DMSO to further dilute test compound solutions. This method of dilution avoids the significant adverse effects of introducing high concentrations of DMSO into the assay. The final concentration of total DMSO carried over into assay reactions should *never* exceed 0.4%.


NOTE: CSM is formulated to help stabilize hydrophobic test compounds in the aqueous environment of the assay mixture. Nonetheless, high concentrations of extremely hydrophobic test compounds diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that test compound dilutions are prepared in CSM immediately prior to assay setup and are considered to be 'single-use' reagents

▪ Assay Scheme ▪

Figure 1. Assay workflow.

NOTE: PPAR α assay protocols includes Day 1 steps and dispensed volumes that are different from the conventional INDIGO assay protocol that some users may be accustomed to when setting up INDIGO's other Nuclear Receptor Assays.

In brief, 200 μ l of Reporter Cells is dispensed into wells of the assay plate and pre-incubated for 4-6 hours. Following the pre-incubation period, culture media are discarded and 200 μ l/well of the prepared 1x-concentration treatment media are added. Following 22-24 hr incubation, treatment media are discarded and Luciferase Detection Reagent is added. The intensity of light emission (in units of 'Relative Light Units'; RLU) from each assay well is quantified using a plate-reading luminometer.



▪ Assay Performance ▪




Figure 2. Agonist dose-response of the rat PPAR α Assay.

Dose-response analyses of rPPAR α Reporter Cells were performed using the reference agonists GW590735 (provided), GW7647 (Tocris) and WY14643 (Tocris). Final assay concentrations were prepared by serial dilution in 4-fold decrements, ranging between 12 μ M and 183 pM. The highest assay concentration of residual DMSO was 0.12%, which has no effect on assay performance. To assess the level of background signal contributed by non-specific factors that cause gratuitous activation of the luciferase reporter gene, “mock” reporter cells were identically treated with GW590735 (mock reporter cells, which contain only the luciferase reporter vector, are not provided with assay kits). Treatment media were removed after 24 hr and LDR was applied. Luminescence was quantified using a GloMax-Multi+ luminometer (Promega). Average relative light units (RLU) and corresponding standard deviation (SD) values were determined for each treatment concentration ($n \geq 6$). Signal-to-background (S/B; fold-activation) and Z' values were calculated as described by Zhang, *et al.* (1999)¹. Non-linear regression and EC₅₀ analyses were performed using GraphPad Prism software.

RESULTS: The high S/B and Z' values, low background and %CV values, and the absence of non-specific reporter activity confirm the robust performance of this rPPAR α Reporter Assay.

¹ Zhang JH, Chung TD, Oldenburg KR. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen.*:4 (2), 67-73.

$$Z' = 1 - [3 * (SD^{Control} + SD^{Background}) / (RLU^{Control} - RLU^{Background})]$$

Rat PPAR α Assay: Antagonist dose-response




Figure 3. Antagonist dose-response of the rat PPAR α assay.

Antagonist dose-response assays were performed using GW6471 (Tocris) and MK886 (Tocris). CSM was first used to prepare serial 4-fold dilutions of each antagonist to generate the desired range of 2x-concentration treatment media. Next, frozen Rat PPAR α Reporter Cells were thawed in CRM, supplemented with a '2x EC₇₅ concentration' of GW590735, and 100 μ l of this treated cell suspension was dispensed into each well of the assay plate. 100 μ l of the prepared series of 2x-concentration treatment media were then dispensed per well, combining with the reporter cells. Final assay concentrations of the respective antagonists ranged between 40 μ M and 2.44 nM, including a 'no antagonist' control (n \geq 6 per treatment; highest [DMSO] \leq 0.12% *f.c.*). Each assay treatment contained \sim 1.3 μ M (approximating EC₇₅) GW590735 as challenge agonist. Assay plates were incubated for 22-24 hrs, then further processed to quantify rPPAR α activity for each treatment condition.

NOTE: RLU values will vary slightly between different production lots of reporter cells, and can vary *significantly* between different makes and models of luminometers.

II. Product Components & Storage Conditions

This rPPAR α Assay contains materials to perform three distinct groups of assays in a 96-well plate format. Reagents are configured so that each group will comprise 32 assays. If desired, however, reagents may be combined to perform either 64 or 96 assays.

The aliquots of Reporter Cells are provided as a single-use reagents. Once thawed, reporter cells can NOT be refrozen or maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

Assay kits are shipped on dry ice. Upon receipt, individual kit components may be stored at the temperatures indicated on their respective labels. Alternatively, the entire kit may be further stored at -80°C.

To ensure maximal viability, "Reporter Cells" must be maintained at -80°C until immediately prior to use.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

<u>Kit Components</u>	<u>Amount</u>	<u>Storage Temp.</u>
▪ rPPAR α Reporter Cells	3 x 0.6 mL	-80°C
▪ Cell Recovery Medium (CRM)	2 x 10.5 mL	-20°C
▪ Compound Screening Medium (CSM)	1 x 45 mL	-20°C
▪ GW590735, 10 mM (in DMSO) (reference agonist for rPPAR α)	1 x 30 μ L	-20°C
▪ Detection Substrate	3 x 2.0 mL	-80°C
▪ Detection Buffer	3 x 2.0 mL	-20°C
▪ Plate frame	1	ambient
▪ Snap-in 8-well strips (white, sterile, cell culture treated wells)	12	ambient

III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

DAY 1

- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO₂ incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8- or 12-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), or deep-well plates, or appropriate similar vessel for generating dilution series of reference compound(s) and test compound(s).
- *Optional*: antagonist reference compound.
- *Optional*: clear 96-well assay plate, cell culture treated, for viewing cells on Day 2.

DAY 2 plate-reading luminometer.

IV. Assay Protocol

Review the entire Assay Protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-11* are performed on **Day 1**, requiring less than 2 hours of bench work and a 4 hr incubation step to complete. *Steps 12-17* are performed on **Day 2**, and require less than 1 hour to complete.

▪ A word about Antagonist-mode assay setup ▪

Receptor inhibition assays expose the Reporter Cells to a constant, sub-maximal concentration (typically between EC₅₀ – EC₈₅) of a known agonist AND the test compound(s) to be evaluated for antagonist activity. This rPPAR α Reporter Assay System kit includes a 10 mM stock solution of **GW590735**, an agonist of rPPAR α that may be used to setup antagonist-mode assays. 1000 nM GW590735 typically approximates EC₇₀ in this cell-based assay. Hence, it presents a reasonable assay concentration of agonist to be used when screening test compounds for inhibitory activity.

We find that adding the reference agonist to the bulk suspension of Reporter Cells (*i.e.*, prior to dispensing into assay wells) is the most efficient and precise method of setting up antagonist assays, and it is the method presented in *Step 5b* of the following protocol. Note that, in *Step 6*, 100 μ l of treatment media is combined with 100 μ l of pre-dispensed [Reporter Cells + agonist]. Consequently, one must prepare the bulk suspension of Reporter Cells to contain a 2x-concentration of the reference agonist. **APPENDIX 1** provides a dilution scheme that may be used as a guide when preparing cell suspension supplemented with a desired 2x-concentration of agonist.

DAY 1 Assay Protocol: All steps must be performed using aseptic technique.

1.) Remove the **2 tubes** of **Cell Recovery Medium (CRM)** from freezer storage, thaw and equilibrate to 37°C using a water bath.

2.) Rapid Thaw of the Reporter Cells: *First*, retrieve the two tubes of **CRM** from the 37°C water bath and sanitize their outside surfaces with a 70% ethanol swab.

Second, retrieve **Reporter Cells** from -80°C storage: 1 tube for 32 assay wells, 2 tubes for 64 assay wells, or 3 tubes for 96 assay wells. *Without delay*, perform a rapid thaw of the frozen cells by transferring **6.4 ml** of pre-warmed CRM into each tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37°C water bath for 5 - 10 minutes. The resulting volume of cell suspension will be **7.0 ml** per tube.

3.) Retrieve the tube of Reporter Cell Suspension from the water bath and sanitize the outside surface with a 70% alcohol swab.

4.) If more than one tube of Reporter Cells is thawed, combine them and gently invert several times to disperse cell aggregates and gain a homogenous cell suspension. Dispense **200 μ l / well** of cell suspension into the assay plate.

NOTE 4.1: Increased well-to-well variation (= increased standard deviation!) will occur if care is not taken to prevent cells from settling during the dispensing period. Likewise, take care to dispense uniform volumes across the assay plate.

NOTE 4.2: Users sometimes wish to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed into a clear 96-well cell culture treated assay plate. Continue to process the assay plate in identical manner to the white assay plate.

5.) Pre-incubate reporter cells: Place the assay plate into a 37°C, \geq 85% humidity, 5% CO₂ incubator for 4 - 6 hours.

Near the end of the 4-6 hour pre-incubation period:

6.) Remove **Compound Screening Medium (CSM)** from freezer storage and thaw in a 37°C water bath.

7.) **Prepare the Test Compound and Reference Compound treatment media at the desired final assay concentrations:** Use **CSM** to prepare an appropriate dilution series of the reference and test compound stocks. Prepare all treatment media at the desired final assay concentrations. In *Step 9*, the prepared treatment media will be dispensed at 200 µl / well into the assay plate. Manage dilution volumes carefully; this assay kit provides **45 ml** of CSM.

NOTE: Total DMSO carried over into assay reactions should never exceed 0.4%.

a. **Agonist-mode assays.** This rPPAR α Reporter Assay System kit includes a 10 mM stock solution of the reference agonist **GW590735**. the following 7-point assay concentration range provides a suitable dose-response: 12000, 4000, 1333, 444, 148, 49.4, and 16.5 nM, and including a 'no treatment' control. **APPENDIX 1** provides an example for generating such a dilution series.

~ or ~

b. **Antagonist-mode assays.** When setting antagonist assays, first supplement a bulk volume of CSM with the challenge agonist GW590735 to achieve the desired final assay-concentration (refer to "*A word about antagonist-mode assay setup*", pg. 8). The agonist-supplemented CSM is then used to generate dilutions of test compound samples to achieve their final assay concentrations.

8.) **At the end of the cell pre-incubation period: Discard the culture media.**

Because the assay plate is composed of a frame with snap-in strip-wells, the practice of physically ejecting media is NOT advised. Complete removal of the media is efficiently performed by tilting the plate on edge and aspirating media using an 8-pin manifold (*e.g.*, Wheaton Science Microtest Syringe Manifold, # 851381) affixed to a vacuum-trap apparatus. Do *not* touch the well bottom, or run the tip of the aspiration device around the bottom circumference of the assay well. Such practices will result in destruction of the reporter cells and greatly increased well-to-well variability.

9.) Dispense **200 µl** of each treatment media into appropriate wells of the assay plate.

10.) Transfer the assay plate into a 37°C, humidified 5% CO₂ incubator for 22 - 24 hours.

NOTE: Ensure a high-humidity ($\geq 85\%$) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.

11.) For greater convenience on Day 2, retrieve the appropriate number of vials of **Detection Substrate and Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

DAY 2 Assay Protocol: Subsequent manipulations do *not* require special regard for aseptic technique, and may be performed on an open bench top.

12.) 30 minutes before intending to quantify receptor activity, remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature. Once at room temperature, gently invert each tube several times to ensure homogenous solutions.

NOTE: Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.

13.) Set the plate-reader to "luminescence" mode. Set the instrument to perform a single 5 second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, *or less*.

14.) *Immediately before proceeding to Step 15:* To read 32 assay wells, transfer the entire volume of 1 vial of Detection Buffer into 1 vial of Detection Substrate, thereby generating a 4 ml volume of **Luciferase Detection Reagent (LDR)**. Mix gently to avoid foaming.

15.) Following 22 - 24 hours incubation in treatment media, remove media contents from each well of the assay plate (as before in *Step 8*).

16.) Add 100 µl of **LDR** to each well of the assay plate. Allow the assay plate to rest at room temperature for at least 5 minutes following the addition of LDR. Do not shake the assay plate during this period.

17.) Quantify luminescence.

V. Related Products

Human PPARα Assay Products	
<i>Product No.</i>	<i>Product Descriptions</i>
IB00111-32	Human PPAR α Reporter Assay System 3x 32 assays in 96-well format
IB00111	Human PPAR α Reporter Assay System 1x 96-well format assay
IB00112	Human PPAR α Reporter Assay System 1x 384-well format assays
Bulk volumes of Assay Reagents may be custom manufactured to accommodate any scale of HTS. Please Inquire.	

Panel of Human PPAR Assays	
<i>Product No.</i>	<i>Product Description</i>
IB00131-32P	Human PPAR γ , PPAR α and PPAR δ Reporter Assay PANEL 32 assays each in 1x 96-well plate

MOUSE PPARα Assay Products	
<i>Product No.</i>	<i>Product Descriptions</i>
M00111-32	Mouse PPAR α Reporter Assay System 3x 32 assays in 96-well format
M00111	Mouse PPAR α Reporter Assay System 1x 96-well format assay

RAT PPARα Assay Products	
<i>Product No.</i>	<i>Product Descriptions</i>
R00111-32	Rat PPAR α Reporter Assay System 3x 32 assays in 96-well format
R00111	Rat PPAR α Reporter Assay System 1x 96-well format assay

LIVE Cell Multiplex (LCM) Assay	
<i>Product No.</i>	<i>Product Descriptions</i>
LCM-01	Reagent volumes sufficient to perform 96 Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats
LCM-05	Reagent in 5x-bulk volume to perform 480 Live Cell Assays in any combination of 1x96-, 2x48-, or 3x32-well assay plate formats
LCM-10	Reagent in 10x-bulk volume to perform 960 Live Cell Assays in any combination of 1x96-, 2x48-, or 3x32-well assay plate formats

Please refer to INDIGO Biosciences website for updated product offerings.

www.indigobiosciences.com

VI. Limited Use Disclosures

Products commercialized by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic or diagnostic use in humans.

“CryoMite” is a Trademark TM of INDIGO Biosciences, Inc. (State College, PA, USA)

Product prices, availability, specifications and claims are subject to change without prior notice.

Copyright © INDIGO Biosciences, Inc. All Rights Reserved.

APPENDIX 1

Example scheme for the serial dilution of GW590735 reference agonist, and the setup of a rPPAR α dose-response assay.

